Global Hormone Replacement Therapy (HRT) Market Analysis 2024-2032 Featuring Abbott, Bayer, Eli Lilly & Co, Novartis, Novo Nordisk, Pfizer, Abbvie, Teva, Dr. Reddy’s Laboratories – ResearchAndMarkets.com

Global Hormone Replacement Therapy (HRT) Market Analysis 2024-2032 Featuring Abbott, Bayer, Eli Lilly & Co, Novartis, Novo Nordisk, Pfizer, Abbvie, Teva, Dr. Reddy’s Laboratories – ResearchAndMarkets.com




Global Hormone Replacement Therapy (HRT) Market Analysis 2024-2032 Featuring Abbott, Bayer, Eli Lilly & Co, Novartis, Novo Nordisk, Pfizer, Abbvie, Teva, Dr. Reddy’s Laboratories – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Hormone Replacement Therapy Market, Size, Forecast 2024-2032, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis” report has been added to ResearchAndMarkets.com’s offering.


The global Hormone Replacement Therapy market is projected to attain a value of US$ 35.86 Billion by 2032. In 2023, the worldwide hormone replacement therapy market was appraised to be worth US$ 20.91 Billion, and it increased at a compound annual growth rate of 6.18% from 2024 to 2032.

Rising R&D and product approvals are expected to aid the growth of the hormonal therapy market. Ascendis Pharma A/S’s drug SKYTROFA received market authorization in January 2022 for treating growth hormone disorders in children and adolescents. In November 2021, I-MAB Biopharma Co., Ltd. partnered with Jumpcan Pharmaceutical Group to market and develop eftansomatropin alfa, named TJ101, in China to treat pediatric growth hormone insufficiency.

The NHSBSA Statistics and Data Science department reported that in 2022-23, 11 million hormone replacement therapy (HRT) items were prescribed in England, an increase of 47% from the previous year. Approximately 2.3 million patients received HRT prescriptions, a 29% increase from the prior year. The report also highlighted that patients in the least deprived areas were prescribed HRT items more than twice as frequently as those in the most deprived areas. Finally, the proportion of HRT prescriptions exempt from prescription charges increased from April 2023, a reversal of the downward trend observed since 2015-16.

The rising prevalence of menopausal symptoms and increased awareness of post-menopausal challenges are key drivers advancing the global HRT market. China’s economic development and policies have increased women’s awareness of self-care and participation in physical examinations. Studies have shown that menopausal symptoms are prevalent in women, with rates as high as 73.8% in community groups and perimenopausal women in rural India being more prone to symptoms compared to pre-menopausal and post-menopausal women.

The prevalence of hormonal imbalances and related disorders is increasing, leading to a rise in demand for hormone replacement therapy. This therapy involves administering synthetic or natural hormones to replace deficient levels of hormones in the body. It is particularly beneficial for individuals experiencing symptoms like hot flashes, mood swings, and reduced libido. The growing awareness of its benefits and the availability of advanced hormone replacement therapies are expected to drive market growth.

United States Hormone Replacement Therapy Market

The US has the biggest market for Hormone Replacement Therapy, with rising utilization among patients over 35 years old. The availability of intensified drugs and an increase in the target population drive market growth. The rise in the release of generic hormone replacement therapy medicines and advances in drug delivery technologies are also contributing factors. NIH reports almost half of post-menopausal US women have used HRT. 1.3 Million American women enter menopause each year.

Conjugated equine estrogens/bazedoxifene tablets are available for menopausal VMS treatment and osteoporosis prevention. The American Thyroid Association has predicted that over 12% of the US population will experience a thyroid disorder during their lifetime, affecting almost 20 million Americans every year. This high incidence of thyroid hormone imbalance is expected to boost the studied market in the region. Additionally, in June 2022, Astellas Pharma Inc. submitted a New Drug Application for fezolinetant, seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Hormone Replacement Therapy Market Company News

  • In February 2023, Korea’s Ministry of Food and Drug Safety approved Pfizer’s NGENLA for treating growth hormone deficiency.
  • Pfizer Inc. finished obtaining Arena Pharmaceuticals in 2022. This acquisition will prompt an upgrade in the portfolio to dermatology, cardiology, gastroenterology, and so forth.
  • In February 2022, MHLW of Japan approved NGENLA of Pfizer, Inc., and OPKO, a long-lasting pediatric growth hormone deficiency treatment. This strategic initiative helps companies expand their customer base in different geographies and boost their revenue.
  • In June 2022, Halozyme Therapeutics launched TLANDO, an oral treatment to replace endogenous testosterone in adult males with a deficiency or absence.
  • In August 2022, Akorn received FDA approval to launch its Generic-Cetrorelix Acetate Injection (0.25 mg). Cetrorelix blocks premature ovulation during ovarian stimulation, making eggs more suitable for fertilization.

Key Attributes:

Report Attribute Details
No. of Pages 230
Forecast Period 2023 – 2032
Estimated Market Value (USD) in 2023 $20.91 Billion
Forecasted Market Value (USD) by 2032 $35.86 Billion
Compound Annual Growth Rate 6.1%
Regions Covered Global

Company Analysis: Overview, Recent Developments, Revenue Analysis

  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly & Company
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Abbvie Inc. (Allergan plc)
  • Teva Pharmaceutical Industries Ltd
  • Dr. Reddy’s Laboratories Ltd

Product Type – Global Hormone Replacement Therapy Market breakup in 5 viewpoints:

  • Estrogen Hormone Replacement Therapy
  • Human Growth Hormone Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy
  • Progestogen Hormone Replacement Therapy

Disease Type – Global Hormone Replacement Therapy Market breakup in 5 viewpoints:

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Others

Route of Administration – Global Hormone Replacement Therapy Market breakup in 3 viewpoints:

  • Oral
  • Parental
  • Others

Distribution Channels – Global Hormone Replacement Therapy Market breakup in 3 viewpoints:

  • Hospitals Pharmacies
  • Retail Pharmacies & Stores
  • Online Pharmacies

Country – Global Hormone Replacement Therapy Market breakup of 25 Countries

  • North America
  • United States
  • Canada
  • Europe
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa¬†

For more information about this report visit https://www.researchandmarkets.com/r/6r3ovl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900